Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 16/20 | 0.82 |
| ▸ | PDE4A | P27815 | 8/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5255478 | 0.94 | CYP2C9 (0.82) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5257398 | 0.90 | CYP2C9 (1.00) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5255586 | 0.89 | CYP2C9 (0.64) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5261020 | 0.85 | CYP2C9 (0.75) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5256469 | 0.85 | CYP2C9 (0.77) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5256052 | 0.84 | CYP2C9 (0.82) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5256706 | 0.84 | CYP2C9 (0.82) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5256241 | 0.84 | CYP2C9 (1.00) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4039946 | 0.83 | CYP2C9 (0.74) | CYP2C9PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5256572 | 0.83 | CYP2C9 (0.74) | CYP2C9PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517895-B1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-03-14 | — | — | EP | disclosed |
| US-7153968-B2 | 8-(biaryl)quinoline PDE4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2006-12-26 | — | — | US | disclosed |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-10-20 | — | — | US | disclosed |
| EP-1517895-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | IL4, PDE4A, PDE4C | CYP2C9 1970/4885PDE4A 2/4885PDE4B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.